Introduction {#s1}
============

Intracerebral hemorrhage (ICH) is an important public health problem that has aroused worldwide concern due to its high mortality and morbidity rates ([@B47]). In addition to primary brain injury that disrupts the physical structure of brain tissue, ICH-induced secondary brain injury (SBI) often leads to severe neurological deficits or even death ([@B68]). Since there has only been minimal progress in the clinical management of ICH, treatment of patients with acute ICH has remained as a challenge for doctors ([@B27]). Therefore, further research is needed for the discovery and development of novel efficacious treatments. There are many pathophysiological changes that have been demonstrated to participate in the process of SBI, including hemoglobin-induced iron overload, oxidative stress, inflammation, cell apoptosis, autophagy, mitochondrial dysfunction, and blood−brain−barrier disruption ([@B80]; [@B8]).

Oxidative stress plays a significant role in ICH-induced SBI. Oxidative stress is involved in pathophysiological processes at multiple stages after ICH ([@B2]). Nuclear factor erythroid-related factor 2 (Nrf2) has been demonstrated to be an important transcription factor that participates in the regulation of oxidative stress and in ameliorating brain damage ([@B64]; [@B71]; [@B75]). Under unstressed states, Nrf2 interacts with its inhibitor, kelch‐like enoyl-coenzyme A hydratase (ECH)‐associated protein 1 (Keap1), to remain in the cytoplasm. Under conditions of oxidative stress, Nrf2 disassociates from Keap1 and translocates to the nucleus to activate the antioxidant response element (ARE), which leads to an increase in the expression of downstream protective proteins such as heme oxygenase-1 (HO-1) and reduced nicotinamide adenine dinucleotide phosphate (NADPH):quinine oxidoreductase-1 (NQO1) ([@B63]).

As a lysosomal degradative pathway, autophagy is essential for survival and maintaining cellular homeostasis. In addition, autophagy is involved in diverse diseases and injuries ([@B19]), including the pathological processes during ICH ([@B9]; [@B31]). Moreover, recent studies have demonstrated that oxidative stress contributes to autophagy ([@B8]). Additionally, by engulfing or degrading oxidative-stress products, autophagy may have positive effects on reducing oxidative damage ([@B10]), such as *via* reactive oxygen species (ROS)/Nrf2/p62 autophagy ([@B19]). As a form of microtubule-associated protein 1A/1B-light chain 3 (LC3), the amount of LC3II is greatly correlated with the formation of autophagosomes and is considered to be an indicator of the extent of autophagy ([@B21]).

As a member of the flavonoid family, luteolin has been shown to exhibit multiple pharmacological effects, such as antioxidative, anti-inflammatory, autophagic-regulatory, apoptotic, and antitumor effects in many disease models ([@B69]; [@B34]; [@B37]; [@B74]). Several studies have shown that luteolin exerts neuroprotective effects both *in vitro* and *in vivo* ([@B70]; [@B4]; [@B25]; [@B34]). However, the effects of luteolin on ICH remain poorly understood.

In this study, we investigated the neuroprotective effects of luteolin in ICH-induced SBI, including potential underlying mechanisms related to regulation of antioxidative processes and autophagy. Moreover, we aimed to assess whether luteolin may represent a potential therapeutic candidate for treating ICH.

Materials and Methods {#s2}
=====================

Animals {#s2_1}
-------

For all pharmacological experiments *in vivo*, adult male Sprague−Dawley rats (250 to 300 g) were purchased from the Animal Center of the Chinese Academy of Sciences (Shanghai, China). The rats had access to water and food *ad libitum* and were group-housed under a 12-h light/dark cycle in animal rooms that had controlled temperature (22 ± 3°C) and humidity (60 ± 5%). All animal experiments were approved by the Ethics Committee of the First Affiliated Hospital of Soochow University. All protocols were in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Animals.

Reagents {#s2_2}
--------

Anti-HO-1 (ab13243), anti-Nrf2 (ab89443), anti-NQO1 (A18; ab28947), anti-histone H3 (ab1791), anti-ubiquitin (ab7780), anti-SQSTM1/p62 (ab56416), and anti-Keap1 antibodies (ab139729) were purchased from Abcam (Cambridge, MA, USA). Anti-β-actin antibody (sc-376421) and normal mouse immunoglobulin G (IgG) (sc-2025) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-β-tubulin (2128L) and anti-LC3B (2775) antibodies were purchased from Cell Signaling Technology (Beverly MA). Protein A + G agarose (P2012), mitochondrial membrane potential assay kits with tetrachloro-tetraethylbenzimidazol carbocyanine iodide (JC-1) (C2006), and ROS assay kits (S0033) were obtained from the Beyotime Institute of Biotechnology (Jiangsu, China). Mitochondrial superoxide (MitoSOX) Red MitoSOX indicator for live-cell imaging (M36008) was purchased from Thermo Fisher Scientific (USA). Luteolin (T1027) was purchased from TargetMol (USA). Horseradish peroxidase (HRP)-conjugated secondary antibodies, anti-rabbit IgG, HRP-linked antibody (7074S), anti-mouse IgG, and HRP-linked antibodies (7076S) were from Cell Signaling Technology (Beverly, MA).

Induction of Intracerebral Hemorrhage {#s2_3}
-------------------------------------

As previously described ([@B38]), a rat model of ICH was established by injecting 100 μl of autologous blood into the brain of each rat. First, Sprague-Dawley rats were intraperitoneally anesthetized with 4% chloral hydrate and were then mounted onto a stereotactic apparatus (Shanghai Ruanlong Science and Technology Development Co., Ltd., China). After exposing the scalp, we drilled a small hole above the right basal ganglia (1.5 mm posterior to bregma, 3.5 mm lateral to the midline). Then, autologous whole blood, which was collected by cardiac puncturing, was injected slowly (5.5 mm ventral to the cortical surface, at 20 μl/min) with a microliter syringe (Hamilton Company, NV, USA) into the stereotaxically positioned hole above the right basal ganglia. The needle was required to stay in place for 5 min to prevent reflux. Finally, scalp was sutured. Representative brain slices from each group are shown in [**Figure 1A**](#f1){ref-type="fig"}.

![Models of intracerebral hemorrhage (ICH) and experimental designs. **(A)** Coronal brainsections of rats in the sham and ICH groups. **(B)** Effects of luteolin on ICH-inducedsecondary brain injury (SBI) *in vivo*. **(C)** Potential mechanisms of luteolin on ICH-induced SBI both *in vivo* and *in vitro*.](fphar-10-01551-g001){#f1}

Experimental Design {#s2_4}
-------------------

### Part I: Potential Effects of Luteolin on Intracerebral Hemorrhage-Induced Secondary Brain Injury in Rats {#s2_4_1}

In this set of experiments, 96 rats (109 rats were used, but only 96 rats ultimately survived) were randomly and equally divided into the following six groups (n = 16 per group): sham group, ICH group, ICH + vehicle group, and three ICH + luteolin treatment groups (i.e., 5, 10, and 20 mg/kg). Rats in the sham group were intracerebrally injected with physiological saline solution (100 μl) into the right basal ganglia at 20 μl/min, after which the microliter syringe stayed in the place for 5 min to prevent reflux. Then, bone wax was used to seal the burr hole and the skin incision was disinfected and sutured, similar to the procedure for rats in the ICH group. ICH-operated rats were injected with 100 μl of autologous whole blood into the right basal ganglia as mentioned above. Luteolin and vehicle \[dimethylsulfoxide (DMSO)\] were injected intraperitoneally at different intervals (10 min, 24 h, and 48 h after ICH) according to the prescribed dose. First, stock solution of luteolin was prepared. We dissolved 50 mg of luteolin into 1 ml of DMSO to make the stock solution. Next, we diluted the stock solution into the corresponding doses with phosphate buffer saline (PBS). Subsequently, we administered intraperitoneal injections at 10 min, 24 h, and 72 h after surgery. At 24 h after ICH, 10 rats per group were tested for behavioral impairments. At 72 h after ICH, six rats per group were euthanized and their brain tissues were used for detection of brain edema. Finally, another six rats were tested in the Morris water maze on the third, fourth, fifth, and sixth day after surgery to assess changes in cognition ([**Figure 1B**](#f1){ref-type="fig"}).

### Part II: Potential Mechanisms of Luteolin on Intracerebral Hemorrhage-Induced Secondary Brain Injury *In Vivo* {#s2_4_2}

In this set of experiments, we used a total of 86 rats, among which 72 rats ultimately survived. The surviving 72 rats were randomly divided into six groups with six rats in each group (consistent with the groupings of Part I above). Brain tissues were collected at 24 h after surgery for Western blotting, and coimmunoprecipitation (Co-IP) analysis ([**Figure 1C**](#f1){ref-type="fig"}).

### Part III: Potential Mechanisms of Luteolin on Oxyhemoglobin-Induced Secondary Brain Injury *In Vitro* {#s2_4_3}

In this set of experiments, primary neurons were cultured and oxyhemoglobin (OxyHb), as a common irritant, was applied to emulate ICH pathophysiology *in vitro*. Primary neurons were treated with different concentrations of luteolin (5, 10, and 20 μM) and OxyHb (10 μM) for 24 h. Finally, Western blotting, JC-1 staining, and MitoSOX staining were performed to assess potential mechanisms of luteolin on OxyHb-induced SBI.

Neurobehavioral Tests {#s2_5}
---------------------

The effects of luteolin on ICH-induced behavioral impairments were examined by monitoring appetite, locomotor activity, and neurological defects in Sprague-Dawley rats with a scoring system that has been previously published ([@B30]); [**Table 1**](#T1){ref-type="table"}). At 24-h post-ICH, 10 rats per group were tested and the data were collected by two investigators blind to the experimental design.

###### 

Neurobehavioral tests.

  Category   Behavior                                                Score
  ---------- ------------------------------------------------------- -------
  Appetite   Finished meal                                           0
             Left meal unfinished                                    1
             Scarcely ate                                            2
  Activity   Walked and reached at least three corners of the cage   0
             Walked with some stimulation                            1
             Almost always lying down                                2
  Deficits   No deficits                                             0
             Unstable walking                                        1
             Unable to walk                                          2

Brain Water Content {#s2_6}
-------------------

As described in a previous study, at 72 h after ICH brain water content was detected by the dry and wet method ([@B65]). In brief, at 72 h after ICH induction, the brain of each rat was harvested immediately. Then the harvested brain tissue was subdivided into the following five parts: cerebellum (CB), ipsilateral cortex (Ipsi-CX), ipsilateral basal ganglia (Ipsi-BG), contralateral basal ganglia (Cont-BG), and contralateral cortex (Cont-CX). The wet weight was recorded immediately after the tissues were weighed with an electronic analytical balance. Subsequently, the dry weight was measured after the samples were dried in a thermostatic drier at 100°C for 72 h. Brain water content was calculated with the following formula: (wet weight − dry weight)/wet weight × 100%.

Morris Water Maze {#s2_7}
-----------------

As described previously ([@B54]), the Morris water maze was performed to assess cognitive function in rats. In short, the rats were trained for 3 days (four trials per day) before the ICH surgery was performed. At 3 to 6 days postsurgery (four trials per day), Sprague-Dawley rats were tested in the Morris water maze. The depth of the water tank was half a meter and the diameter was 180 cm. First, the tank was filled with water (20--22°C) to a height of 30 cm, after which ink was added to the water. Black-corded fabric was used to wrap the target platform. The platform, which was 10 cm in diameter, was positioned at 2 cm beneath the surface of the water. The starting location of the rat was altered with each new trial. Moreover, the visual points of reference were kept unchanged around the pool. Each trial was terminated when the rat found the platform or when the trial had lasted for 59 s. Rats were allowed to rest for 20 s on the platform after each trial. During the training phase, the rats were given 1 min to find the platform in the pool. If the rats failed to find the platform, we then guided them to the platform with a rod. The rats were allowed to stay at the platform for 20 s to strengthen their memory before they were removed. The swimming path length, latency, and speed to find the platform for each trial were automatically recorded on a computer. The parameters were used to evaluate learning/memory abilities and cognitive function.

Western Blotting {#s2_8}
----------------

After induction of ICH for 24 h, brain samples from the right basal ganglia of each rat were collected and homogenized. Both the brain samples collected and extracted cells (for *in vitro* experiments) were lysed in ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China). After centrifugation at 12,000 rpm at 4°C for 15 min, the supernatant from each sample was collected. Subsequently, we measured protein concentrations *via* a bicinchoninic (BCA) protein assay kit (Beyotime Institute of Biotechnology). After mixing each sample with sodium dodecyl sulfate (SDS) sample buffer, the protein samples were boiled for 5 min at 100°C. After being separated in a 10% SDS- polyacrylamide gel electrophoresis (PAGE) gel, the protein samples (30 μg per lane) were electrophoretically transferred to a polyvinylidene-difluoride (PVDF) membrane (Millipore Corporation, Billerica, MA, USA), which was then blocked with non-fat milk in PBS-Tween 20 (PBST) for 1 h at room temperature. The membrane was then incubated with primary antibodies overnight at 4°C. The titers of antibodies were as follows: anti-HO-1 antibody (ab13243, 1:1,000 dilution), anti-Nrf2 antibody (ab89443, 1:1,000 dilution), anti-NQO1 antibody (A180; ab28947, 1:1,000 dilution), anti-SQSTM1/p62 antibody (ab56416, 1:1,000 dilution), anti-Keap1 antibody (ab139729, 1:1,000 dilution), LC3B antibody (Cell Signaling Technology, 2775s, 1:1,000 dilution), and anti-ubiquitin antibody (ab7780, 1:1,000 dilution). Furthermore, anti-β-tubulin antibody (Cell Signaling Technology, 2128L, 1:1,000 dilution), anti-histone H3 antibody (ab1791, 1:1,000 dilution), and anti-β-actin antibody (sc-376421, 1:500 dilution) served as loading controls. On the next day, after being washed with PBST (PBS + 0.1% Tween 20), each membrane was incubated with HRP-conjugated secondary antibodies for 1 h at room temperature, after which each membrane was subsequently washed three times with PBST. Protein bands were then revealed *via* an enhanced chemiluminescence (ECL) kit (Beyotime), and protein bands were analyzed *via* ImageJ software (NIH, Bethesda, MD, USA).

Nuclear and Cytoplasmic Protein Extractions {#s2_9}
-------------------------------------------

Nuclear and cytoplasmic proteins were extracted with a nuclear and cytoplasmic protein extraction kit (P0027, Beyotime) according to the manufacturer's instructions.

Ubiquitin Analysis {#s2_10}
------------------

First, the collected brain samples were lysed in ice-cold RIPA lysis buffer. Then the total protein samples were incubated with 1 μg of anti-Nrf2 antibody or IgG (negative control) overnight at 4°C with agitation. Subsequently, the immune complex was incubated with protein A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for 4 h and was then precipitated under rotary agitation. Finally, the immunoprecipitated proteins were analyzed by SDS−PAGE and immunoblotting with specific antibodies, including anti-Nrf2 and anti-ubiquitin antibodies.

Cell Culture {#s2_11}
------------

As described previously ([@B58]), primary rat cortical neurons were isolated from 17-day-old rat embryos. In short, we separated the meninges and blood vessels of the brains, which were subsequently rinsed with PBS. Subsequently, the harvested brain tissue was digested with 0.25% trypsin at 37°C for 5 min. The digested brain tissues were then washed with PBS and the resultant brain suspension was centrifuged at 1,500 rpm for 5 min. The resuspended cells were inoculated into 6-well and 12-well plates that were precoated with poly-D-lysine (Sigma, USA). Regarding the inoculation density, we inoculated 2\*10^6^ neurons per well into the 6-well plates, and inoculated 1\*10^5^ neurons per well into 12-well plates. Subsequently, the dissociated cortical neurons were cultured in Neurobasal medium (Gibco, Carlsbad, CA, USA) that was supplemented with 0.5 mM of GlutaMAX, 2% B-27, 50 U/ml of streptomycin, and 50 U/ml of penicillin (Invitrogen, Grand Island, NY, USA). Finally, the neurons were placed in an incubator at a constant temperature of 37°C and with humidified air containing 5% CO~2~. We changed half of the culture medium every 2 days for 1 week, after which the neurons were harvested for subsequent assays.

Intracerebral Hemorrhage Models *In Vitro* {#s2_12}
------------------------------------------

We established an *in vitro* of ICH model by using OxyHb which stimulates neurons and induces pathophysiological changes in neurons that are similar to those from ICH. OxyHb (10 μM) was added in Neurobasal medium to stimulate neurons for 24 h at 37°C in 5% CO~2~.

Tetrachloro-Tetraethylbenzimidazol Carbocyanine Iodide Staining {#s2_13}
---------------------------------------------------------------

The mitochondrial membrane potential assay kit was used to detect changes in the mitochondrial membrane potential of neurons, while JC-1 staining was used as an indicator of mitochondrial damage (Beyotime, China), both of which were used according to the manufacturer's protocol. After being washed with PBS, pretreated neurons were incubated with 1 ml of JC-1 working solution per sample at 37°C for 20 min. Then neurons were washed twice with JC-1 staining buffer. After adding 4′,6-diamidino-2-phenylindole (DAPI) (DAPI Fluoromount-G, SouthernBiotech, USA), we observed the neurons under a fluorescent microscope ([@B65]).

Measurement of Mitochondrial Superoxide {#s2_14}
---------------------------------------

After being treated with OxyHb (10 μM) to mimic ICH *in vitro*, luteolin (10 μM) or vehicle was added into the medium of primary neurons. After 24 h, we firstly prepared the stock solution of 5-mM MitoSOX reagent. Then, 13 μl of DMSO was added to a vial of MitoSOX Red MitoSOX indicator (Thermo Fisher Scientific, USA) containing 50 μg of content. Then, 5-μM MitoSOX reagent working solution was made by diluting the stock solution of 5-mM MitoSOX reagent (mentioned above) with PBS. The neurons of all groups were covered with 5-μM MitoSOX reagent working solution and were incubated at 37°C for 10 min in the dark. Then neurons were mounted in PBS for analysis and imaging after being washed three times with warm PBS.

Statistical Analysis {#s2_15}
--------------------

We used GraphPad Prism 6 to perform statistical analyses of all experimental data. In addition to neurobehavioral scorings, which are expressed as the median with the interquartile range, all other data are expressed as the mean ± standard deviation (SD). The Mann-Whitney U test was used to analyze neurobehavioral scorings. For all other data, one-or two-way analyses of variance (ANOVAs) were applied to determine significant differences among more than two groups, and we used Tukey's *post-hoc* tests to determine pairwise differences among the groups. Differences were considered statistically significant at p \< 0.05.

Results {#s3}
=======

Luteolin Attenuates Intracerebral Hemorrhage-Induced Secondary Brain Injury *In Vivo* {#s3_1}
-------------------------------------------------------------------------------------

To evaluate the effect of luteolin on brain injury following ICH, autologous blood was injected into the basal ganglia of rats. Coronal brain sections are shown in [**Figure 1A**](#f1){ref-type="fig"}. Behavioral testing was performed at 24 h after ICH. Damage of neurobehavioral abilities of the ICH group was significantly more severe than that of the sham group, and this impairment was partly alleviated after intraperitoneal injection of 10 mg/kg or 20 mg/kg of luteolin for 24 h ([**Figure 2A**](#f2){ref-type="fig"}). We found that sham group *vs.* ICH group, Z = −4.077, P \< 0.0001; ICH + vehicle group *vs.* ICH + 5 mg/kg luteolin group, Z = −0.390, P = 0.8471; ICH + vehicle group *vs.* ICH + 10 mg/kg luteolin group, Z = −2.403, P = 0.0234; ICH + vehicle group *vs.* ICH + 20 mg/kg luteolin group, Z = −2.262, P = 0.024.

![Luteolin ameliorates intracerebral hemorrhage (ICH)-induced neuronal injury. After injection of autologous blood, Sprague-Dawley rats were treated with luteolin (5, 10, 20 mg/kg) or vehicle. **(A)** The neurological scores of rats in the six groups were evaluated and resultant scores are reported in [**Table 1**](#T1){ref-type="table"} (\*\*p \< 0.01 *vs.* sham group; \#p \< 0.05 *vs.* ICH + vehicle group; n = 10). **(B)** The effects of luteolin on brain water content were examined. All data are shown as the mean ± SD (\*\*p \< 0.01 *vs.* sham group; \#\#p \< 0.01 *vs.* ICH + vehicle group; n = 10). **(C**--**F)** Effects of luteolin treatment on cognitive behavioral impairments induced by autologous blood were tested *via* the Morris water maze. **(C)** Representative swimming-path traces of the rats in each group are displayed. **(D)** Swimming speed at the beginning of the test (third-day postsurgery), **(E)** distances and **(F)** escape latencies from four trials per day for a total of 4 days are shown. The values are shown as the mean ± SD (\*P \< 0.05, \*\*P \< 0.01; n = 6).](fphar-10-01551-g002){#f2}

Then, we measured brain water content to assess the effect of luteolin on brain edema after ICH. We found that the brain water content was significantly higher in the ICH group compared with that in the sham group in the Ipsi-BG and Ipsi-CX. However, the rise of brain water content in these brain regions was inhibited *via* luteolin (10 or 20 mg/kg). In contrast, there were no significant differences in the brain water content within the Cont-BG, Cont-CX, or CB among the six experimental groups ([**Figure 2B**](#f2){ref-type="fig"}).

In addition, to examine the role of luteolin in cognitive changes induced by ICH, rats were tested in the Morris water maze test ([**Figures 2C--F**](#f2){ref-type="fig"}). Longer escape latencies and swimming distances were observed in rats from the ICH group compared with these parameters in the sham group. In contrast, there were no significant differences in these parameters among the ICH group, and ICH + vehicle group, or ICH + 5 mg/kg luteolin group. However, data from rats in the ICH + 10 mg/kg luteolin group and ICH + 20 mg/kg luteolin group demonstrated that the ICH-induced increases in escape latencies and swimming distances were partially ameliorated *via* luteolin treatments ([**Figures 2E, F**](#f2){ref-type="fig"}). For latencies, the following results were found: third-day postsurgery, F (3, 120) = 88.48, P \< 0.0001; on the fourth-day postsurgery, F (3, 120) = 157.4, P \< 0.0001; on the fifth-day postsurgery, F (3, 120) = 139.6, P \< 0.0001; and on the sixth-day postsurgery, F (3, 120) = 112.4, P \< 0.0001. For swimming distance, the following results were found: on the third-day postsurgery, F (3, 120) = 72.53, P \< 0.0001; on the fourth-day postsurgery, F (3, 120) = 119.2, P \< 0.0001; on the fifth-day postsurgery, F (3, 120) = 115.7, P \< 0.0001; and on the sixth-day postsurgery, F (3, 120) = 279.9, P \< 0.0001. Additionally, we found there were no significant differences in the swimming speed of all the groups at the beginning of the test (third-day postsurgery) ([**Figure 2D**](#f2){ref-type="fig"}). Overall, luteolin exerted a partial rescuing effect on the brain injury induced by ICH, and this effect was evident at doses of 10 and 20 mg/kg.

Luteolin Promotes Activation of the Nrf2 Pathway and Enhances Nrf2 Nuclear Translocation Following Intracerebral Hemorrhage *In Vivo* {#s3_2}
-------------------------------------------------------------------------------------------------------------------------------------

To explore the effects of luteolin on the Nrf2 signaling pathway after ICH, at 24 h after ICH, we detected the protein levels of both Nrf2 and downstream antioxidative proteins of Nrf2 (HO-1 and NQO1) *via* Western blotting. At 24 h after ICH Nrf2 levels were not significantly elevated compared to those of the sham group; however, treatment with luteolin significantly elevated Nrf2 levels at 24 h after ICH ([**Figure 3A**](#f3){ref-type="fig"}). We obtained similar results when we detected the protein levels of HO-1 and NQO1 ([**Figures 3B, C**](#f3){ref-type="fig"}). The promotion effect was only apparent when the dose of luteolin reached 10 and 20 mg/kg. Moreover, to further explore the mechanisms of luteolin on regulating the Nrf2 signaling pathway, we evaluated Nrf2 nuclear translocation by extracting and assaying nuclear and cytoplasmic proteins. As shown in [**Figure 3D**](#f3){ref-type="fig"}, after ICH, nuclear Nrf2 protein levels were increased and corresponded to concomitantly decreased levels of cytoplasmic Nrf2 protein compared to those in the sham group, and this effect was significantly amplified after administration of luteolin (10 mg/kg). These findings suggest that luteolin increased Nrf2 nuclear translocation to activate subsequent pathways at 24 h after ICH, possibly to induce anti-oxidative processes.

![Luteolin treatment promotes intracerebral hemorrhage (ICH)-induced activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway and enhances Nrf2 nuclear translocation. After injecting of autologous blood and luteolin (5, 10, 20 mg/kg), we extracted brain tissue proteins in each group at 1 day after ICH. **(A**--**C)** Protein levels of Nrf2, heme oxygenase-1 (HO-1), and reduced nicotinamide adenine dinucleotide phosphate (NADPH):quinine oxidoreductase 1 (NQO1) were examined by Western blotting. In the quantitative analysis of protein levels, the mean values of proteins in the corresponding sham groups were normalized to 1.0. Data are presented as the mean ± SD (\*p \< 0.05 *vs.* sham group and \#\#p \< 0.01 *vs.* ICH + vehicle group; n = 6). **(D)** Western-blot analysis of Nrf2 in the nucleus and cytoplasm at 24 h after ICH. Relative protein levels are shown. H3 and β-tubulin served as loading controls. All data are shown as the mean ± SD \[\#\#p \< 0.01 *vs.* ICH + vehicle group (nuclear); \*\*p \< 0.01 *vs.* ICH + vehicle group (cytoplasmic); n = 3\]. Full images for Western blots in figures were shown in [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.](fphar-10-01551-g003){#f3}

Luteolin Activates the P62-Keap1-Nrf2 Pathway and Enhances Autophagy After Intracerebral Hemorrhage by *In Vivo* {#s3_3}
----------------------------------------------------------------------------------------------------------------

We next further explored the effects and possible mechanisms of luteolin on the Nrf2 signaling pathway after ICH. Here, we focused on Keap1, which is an important Nrf2 repressor that binds to Nrf2 in the absence of stimulation and is related to ubiquitination of Nrf2 to mediate proteasomal degradation. As shown in [**Figure 4A**](#f4){ref-type="fig"}, the level of Keap1 in brain tissue was decreased at 24 h after ICH compared to that in the sham group but it was not obvious. However, the administration of medium and high doses of luteolin (10, 20 mg/kg) significantly decreased Keap1 levels compared to that in the ICH + vehicle group. p62, which is another type of autophagy-adaptor protein, has been documented to associate with Nrf2 signaling and autophagy *via* binding with Keap1. Finally, p62 sequesters Keap1 into autophagosomes for degradation during autophagy ([@B19]). Hence, we next examined the expression of p62 as an indicator of autophagy. As is shown in [**Figure 4B**](#f4){ref-type="fig"}, a lower expression of p62 was found in the ICH group compared with that in the sham group. In contrast, luteolin (10, 20 mg/kg) reduced the expression of p62 compared to that in the ICH + vehicle group. Next, we evaluated the level of LC3II, which is another autophagy-related marker. The expression of LC3II was increased at 24 h after ICH and the treatment of luteolin (10, 20 mg/kg) further increased LC3II expression. This finding suggests that luteolin enhanced autophagy and led to the activation of the downstream Nrf2 signaling pathway ([**Figure 4C**](#f4){ref-type="fig"}).

![Luteolin promotes autophagy to activate the sequestosome 1 (p62)/kelch‐like enoyl-coenzyme A hydratase (ECH)‐associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and inhibits the ubiquitination of Nrf2 *in* *vivo*. Rats were subjected to intracerebral hemorrhage (ICH), and were then injected with luteolin (5, 10, 20 mg/kg) or vehicle. At 24 h after ICH, brain tissues were collected and Western-blot analysis was performed. The protein levels of Keap1 **(A)**, p62 **(B)**, and LC3 **(C)** were evaluated in the six groups. Data are presented as the mean ± SD (\*P \< 0.05 *vs.* sham group; \#P \< 0.05, \#\#P \< 0.01 *vs.* ICH + vehicle group; n = 6). **(D)** The interaction between Nrf2 and ubiquitin *in vivo* was analyzed *via* coimmunoprecipitation. Ubiquitin was immunoprecipitated with the anti-Nrf2 antibody and immunoglobulin G (IgG) was used as a negative control. Luteolin inhibited the ubiquitination of Nrf2. Full images for Western blots in figures were shown in [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.](fphar-10-01551-g004){#f4}

Luteolin Protects Intracerebral Hemorrhage-Induced Injury *Via* Inhibition of Nrf2 Ubiquitination *In Vivo* {#s3_4}
-----------------------------------------------------------------------------------------------------------

Reduced Nrf2 ubiquitylation has been recognized to enhance the stability of Nrf2 and to promote the activation of the Nrf2 signaling pathway ([@B19]). Therefore, we examined the level of Nrf2 ubiquitination *via* Co-IP assays to further explore the mechanism of luteolin in influencing the Nrf2 signaling pathway. As shown in [**Figure 4D**](#f4){ref-type="fig"}, the interaction between Nrf2 and ubiquitin was obvious in the sham group. Compared with that in the ICH + vehicle group, treatment with luteolin (10 mg/kg) inhibited the interaction between Nrf2 and ubiquitin.

Luteolin Ameliorates Oxyhemoglobin-Induced Mitochondrial Injury *In Vitro* {#s3_5}
--------------------------------------------------------------------------

The Nrf2 signaling pathway has been recognized as a significant pathway for exerting antioxidative processes and downregulating the accumulation of ROS ([@B75]). As an important indicator for assessing the level of oxidative-stress damage, we used the MitoSOX Red MitoSOX indicator to measure mitochondrial ROS. OxyHb was used to simulate ICH pathophysiology *in vitro* in cultured primary neurons. After being treated with OxyHb (10 μM), using a fluorescent microplate reader, we found increased ROS in the OxyHb group and OxyHb + vehicle group compared to that in the sham group, but this OxyHb-induced increase was inhibited *via* luteolin (10 μM) treatment ([**Figures 5A, B**](#f5){ref-type="fig"}). JC-1 staining is an ideal fluorescent probe for examining changes in the mitochondrial membrane potential (△Ψt). In the absence of stimulation, JC-1 binds to the mitochondrial matrix in the form of J-aggregates, producing red fluorescence. As shown in [**Figure 5C**](#f5){ref-type="fig"}, after treatment with OxyHb, a decrease in red fluorescent intensity and an increase in green fluorescence intensity were observed in the OxyHb group and the OxyHb + vehicle group, which indicated a loss of the mitochondrial membrane potential and openings of mitochondrial permeability transition pores (MPTPs). However, the administration of luteolin (10 μM) reversed such effects. In conclusion, luteolin reduced the production of mitochondrial ROS and played a significant role in mitochondrial protection following OxyHb.

![Luteolin attenuates oxyhemoglobin (OxyHb)-induced increases in mitochondrial reactive oxygen species (ROS) and mitochondrial injury *in vitro*. Primary neurons were cultured and were incubated with or without OxyHb (10 μM) and/or co-incubation with luteolin (10 μM) for 24 h. Representative images of mitochondrial superoxide (MitoSOX) staining **(A)**, relative MitoSOX fluorescence intensities analysis **(B)**, and tetrachloro-tetraethylbenzimidazol carbocyanine iodide (JC-1) staining images **(C)** are shown, which indicated the levels of mitochondrial ROS and the degrees of mitochondrial injury. The scale bar = 5 μm **(A)**. Data are presented as the mean ± SD (\*\*P \< 0.01 vs. control group; ^\#^P \< 0.05 vs. OxyHb \[10 μM\] + vehicle group; n = 3) **(B)**, whereas the scale bar = 50 μm **(C)**.](fphar-10-01551-g005){#f5}

Luteolin Protects Neurons From Oxyhemoglobin-Induced Injury *via* Activation of the P62/Keap1/Nrf2 Pathway *In Vitro* {#s3_6}
---------------------------------------------------------------------------------------------------------------------

To further investigate the role of luteolin in the p62/Keap1/Nrf2 pathway after ICH, we examined the protein levels of p62, Keap1, and LC3II *via* Western blotting of primary neurons *in vitro*. The expression levels of both p62 and Keap1 were decreased after treatment with OxyHb (10 μM), as compared with these levels in the control group. However, the protein levels of both p62 or Keap1 were significantly decreased following co-treatment with OxyHb (10 μM) and luteolin (10 μM), as compared with these levels following OxyHb (10 μM) + vehicle. In order to explore the potential mechanisms of luteolin in the correlation between the p62/Keap1/Nrf2 pathway and autophagy, chloroquine (CQ)---which is an autophagy inhibitor---was used. We found that the luteolin-induced decreases in the protein levels of p62 or Keap1 were reversed after the co-treatment with OxyHb (10 μM), CQ (30 μM), and luteolin (10 μM). Additionally, analysis of LC3II protein levels recapitulated this phenomenon. Pre-treatment with OxyHb (10 μM) and luteolin (10 μM) up-regulated the expression of LC3II, which suggested that there were elevated levels of autophagy, compared with those in the OxyHb (10 μM) + vehicle group. Moreover, this change was reversed *via* CQ ([**Figures 6A--D**](#f6){ref-type="fig"}). In summary, we obtained similar results to those in our *in vivo* experiments, which confirmed the role of luteolin in promoting the activation of the p62/Keap1/Nrf2 pathway.

![Luteolin promotes the activation of the sequestosome 1 (p62)/kelch‐like enoyl-coenzyme A hydratase (ECH)‐associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway *in vitro*. **(A)** Western blotting showing that compared to that in the control group, after oxyhemoglobin (OxyHb) stimulation, the protein level of p62 or Keap1 was decreased and the expression of LC3II was increased. Additionally, these changes were magnified with co-treatment of OxyHb (10 μM) and luteolin (10 μM). Moreover, the above changes were reversed *via* chloroquine (CQ). **(B)** Quantification of the protein levels of p62 in the various groups. Data are presented as the mean ± SD \[\*P \< 0.05 *vs.* control group; ^&&^P \< 0.01 *vs.* OxyHb (10 μM) + vehicle group; ^\#\#^P \< 0.01 *vs.* OxyHb (10 μM) + luteolin (10 μM) group; n = 3\]. **(C)** Quantification of the expression of Keap1 in the various groups. Data are presented as the mean ± SD \[\*P \< 0.05 *vs.* control group; ^&^P \< 0.05 *vs.* OxyHb (10 μM) + vehicle group; ^\#\#^P \< 0.01 *vs.* OxyHb (10 μM) + luteolin (10 μM) group; n = 3\]. **(D)** Quantification of the relative levels of LC3II in the various groups. Data are presented as the mean ± SD \[\*P \< 0.05 *vs.* control group; &&P \< 0.01 *vs.* OxyHb (10 μM) + vehicle group; ^\#\#^P \< 0.01 *vs.* OxyHb (10 μM) + luteolin (10 μM) group; n = 3\]. Full images for Western blots in figures were shown in [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.](fphar-10-01551-g006){#f6}

Discussion {#s4}
==========

Over the past several decades, oxidative stress has been found to be involved in the pathogenesis and development of many diseases, including ophthalmic diseases ([@B40]; [@B44]), diabetes ([@B48]), cardiovascular diseases ([@B35]; [@B39]; [@B52]), atherosclerosis ([@B11]), arthritis ([@B3]; [@B23]), dermatological diseases ([@B49]), respiratory diseases ([@B17]), hepatic diseases ([@B28]), urinary system diseases ([@B1]), cancer ([@B45]), neurodegenerative disorders ([@B20]), and other nervous system diseases ([@B6]; [@B41]; [@B42]). Moreover, oxidative stress also participates in pathological processes after ICH ([@B2]). Inhibition of oxidative stress has been demonstrated to improve the prognosis of ICH, ameliorate neurobehavioral impairments, and reduce brain edema ([@B66]; [@B75]; [@B56]; [@B65]). Autophagy is involved in the pathophysiological processes of various diseases, as well as in ICH ([@B16]). In recent years, the crosstalk between autophagy and anti-oxidative processes has received considerable attention, and related studies have suggested that autophagy may enhance antioxidative processes in a variety of disease models ([@B12]; [@B15]; [@B29]).

ICH exhibits high disability and mortality rates. Moreover, ICH has become a heavy burden for global health care systems and societies ([@B53]). Supportive medical care has represented the main treatment for ICH but has yielded an insufficient efficacy ([@B14]). Numerous studies have been carried out in order to further investigate the mechanisms of ICH-induced SBI. Many kinds of recombinant proteins, compounds, drugs, and other agents---including recombinant complement component 1q (C1q)/tumor necrosis factor (TNF)-related protein 9 (rCTRR9), recombinant osteopontin (rOPN), isoliquiritigenin, andrographolide, and melatonin---have been reported to exert neuroprotective effects after ICH by alleviating brain injury, inhibiting neuronal apoptosis, suppressing oxidative stress, down-regulating inflammatory damage, and protecting the blood−brain barrier ([@B75]; [@B13]; [@B32]; [@B65]; [@B78]). However, the protective effects of these neuroprotective agents are still lacking in clinical applications, and many such agents include problematic side effects. Therefore, there is a continued need to further identify and develop novel drugs that are both safe and efficacious in the treatment of ICH.

Luteolin is a member of the naturally occurring flavonoid family and has various beneficial bioactivities. Numerous studies have revealed anti-inflammatory, antioxidative, anti-apoptotic, autophagic-regulatory, anti-viral, anticancer, and metabolic effects of luteolin, which have been confirmed in many different disease models ([@B18]; [@B77]; [@B43]; [@B7]; [@B33]; [@B61]; [@B73]; [@B22]). In addition, in studies on ischemic stroke ([@B46]; [@B60]; [@B34]), traumatic brain injury ([@B70]), neurodegenerative diseases ([@B25]; [@B76]), and other neurological diseases, luteolin has been shown to exert therapeutic effects. Compared with other properties of agents, luteolin has a wide range of sources and is cost-effective. Moreover, because of its lipophilicity, luteolin is able to freely penetrate the blood-brain barrier even if it is administered peripherally ([@B51]). However, to the best of our knowledge, the impact of luteolin on ICH-induced SBI has remained unclear. Hence, our study focused on this direction and attempted to elucidate any underlying mechanisms.

In this study, we demonstrated that luteolin enhanced the activation of the Nrf2 pathway and enhanced Nrf2 nuclear translocation after ICH. Nrf2 is known to regulate various antioxidant enzymes to protect cells against oxidative stress and is essential for the clearance of hematomas ([@B79]; [@B22]). Numerous studies have demonstrated that activation of the Nrf2 signaling pathway is beneficial in alleviating ICH-induced SBI. Additionally, activation of the Nrf2 signaling pathway has been suggested to be an underlying mechanism related to the efficacies of other agents in ICH treatment ([@B26]; [@B66]; [@B75]). Moreover, previous studies have revealed that luteolin upregulates Nrf2 expression and triggers Nrf2 translocation in various disease models, including brain diseases ([@B70]; [@B33]; [@B61]; [@B37]). Our present findings were consistent with those of the previous studies.

Previous studies have revealed that there are differential effects of luteolin on the Nrf2 signaling pathway in different cell lines. For example, luteolin was recognized as an Nrf2 inhibitor and suppressed the activity of the Nrf2/ARE pathway in human lung carcinoma A549 cells ([@B62]). Son et al. found that luteolin has a bidirectional regulation of the Nrf2 pathway at different stages of disease development ([@B55]). These findings indicate that the role of luteolin in the regulation of the Nrf2/ARE pathway may be different in different cell types. At the same, the biological timing context may be a significant factor.

As a type of LC3-binding protein, p62 functions as a critical autophagy-adaptor protein and promotes the selective degradation of proteins *via* autophagy ([@B24]). The results of related studies have indicated that by physically isolating Keap1 and impairing the ubiquitylation of Nrf2, p62 mediates the activation of Nrf2 and its downstream pathways and plays an important role in antioxidative processes ([@B19]). In the process of exploring new drugs, up-regulation of autophagy has been found in numerous disease-model studies ([@B72]; [@B50]) and activation of the p62/Keap1/Nrf2 pathway has been shown to play a role in alleviating systemic diseases ([@B59]; [@B57]) and in ameliorating brain injury, such as ischemic stroke ([@B67]). Our present findings were similar to those described above. In addition, luteolin has been found to enhance autophagy in studies of other diseases ([@B70]; [@B18]; [@B5]). Additionally, the administration of autophagic inhibitors such as CQ, has been shown to be associated with exacerbating disease progression ([@B72]; [@B67]). These findings are consistent with our present results, such that we found that luteolin enhanced autophagy and activated the p62/Keap1/Nrf2 pathway, and this effect was reversed by the autophagic inhibitor, CQ, in our ICH model ([**Figure 7**](#f7){ref-type="fig"}).

![Potential mechanisms of luteolin in ameliorating intracerebral hemorrhage (ICH)-induced secondary brain injury (SBI). Luteolin enhances autophagy, activates the sequestosome 1 (p62)/kelch‐like enoyl-coenzyme A hydratase(ECH)‐associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, and plays an important role in neuroprotection and anti-oxidative processes, which suggests that luteolin may represent a promising drug for ameliorating ICH-induced SBI.](fphar-10-01551-g007){#f7}

Above all, our findings suggest that luteolin may represent a novel treatment for ICH-induced SBI. However, our study had some limitations. Our study used Sprague−Dawley male rats as animal models. However, in clinical epidemiological studies, there are also female patients with ICH, and the incidence of ICH in elderly patients is higher than in younger patients. Furthermore, the specific details of luteolin promoting autophagy and affecting the p62/Keap1/Nrf2 pathway remain unclear.

Conclusion {#s5}
==========

Taken together, our results demonstrate that autophagy increases slightly after ICH, which activates the p62/Keap1/Nrf2 pathway and upregulates the expression levels of its downstream antioxidant proteins, HO-1 and NQO1, but that effect was not obvious. In contrast, the administration of luteolin significantly amplified the above effects and may have the potential to attenuate ICH-induced SBI in ICH patients.
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